Greffex is a genetic engineering company based in Aurora, CO, that specializes in developing next-generation adenoviral vector technology and a superior vaccine platform. Their innovative approach involves fully deleting all endogenous adenoviral genes without the use of helper viruses, resulting in vaccines that better focus the immune system, minimize interference, and allow for multiple repeat uses of the same construct.
With a strong focus on vaccine commercialization, Greffex has made significant strides in the field, with three vaccine candidates currently in clinical trials, including a COVID-19 vaccine. Their patented technology allows for the creation of vaccines in just 3-4 weeks, with the ability to produce millions of doses quickly and at a fraction of the cost of traditional vaccine production. Greffex's vectors are known for their cleanliness, safety, stability, and versatility, making them a promising solution for mitigating the current pandemic and future pandemics.
Generated from the website